Full-Time

Data Engineer

Posted on 9/27/2024

Scribe Therapeutics

Scribe Therapeutics

51-200 employees

Develops CRISPR-based genetic medicine solutions

Compensation Overview

$80k - $120k/yr

+ Incentives

Junior, Mid

Alameda, CA, USA

Requires onsite presence in Alameda, CA for three to four days per week.

Category
Data Engineering
Data & Analytics
Required Skills
Microsoft Azure
Python
MySQL
Data Science
Apache Spark
SQL
Java
Postgres
AWS
Scala
MongoDB
Data Analysis
Cassandra
Google Cloud Platform
Requirements
  • Experience with big data and data science tools and development, as well as database and data management best practices
  • Strong proficiency in programming languages such as Python, Java, or Scala, as well as SQL for data manipulation and query optimization.
  • Familiarity with cloud platforms and services, such as AWS, Azure, or GCP, and their data-related offerings (e.g., Amazon Redshift, Google BigQuery).
  • Experience with data integration and ETL tools such as Apache Spark, Apache Airflow, or Glue in AWS
  • Solid understanding of database systems, both relational (e.g., PostgreSQL, MySQL) and NoSQL (e.g., MongoDB, Cassandra).
  • Knowledge of data modeling and database design principles to ensure efficient storage and retrieval of data.
  • Knowledge of data governance, data security, and compliance frameworks to ensure data integrity and privacy.
  • Familiarity with machine learning concepts and frameworks to support data science initiatives.
  • Ability to communicate and work effectively with internal software and data science teams, external IT contractors and members of other functional teams
  • At least 2 years of experience working in an academic or industry lab, with a proven track record of hands-on experience developing data engineering projects, databases, or data science tools.
  • Demonstrated quantitative and scientific thinker as evidenced by a strong publication record
  • Ability to work both independently and collaboratively in a fast-paced, interdisciplinary research team
Responsibilities
  • Design, construct, and maintain data systems and pipelines for efficient and reliable data ingestion, processing, and storage.
  • Develop and implement data integration and ETL (Extract, Transform, Load) processes to ensure data quality, accuracy, and consistency.
  • Build scalable and optimized databases, data warehouses, and data lakes to support the organization's data needs.
  • Implement and manage data governance practices, including data security, privacy, and compliance.
  • Automate data workflows, data validation, and data quality checks to ensure data accuracy and reliability.
  • Collaborate with data scientists and bioinformatics scientists to maintain code libraries/pipelines that implement and support Machine Learning (ML) workflows while integrating them with internal storage and metadata-management systems
  • Build and maintain MLOps system for supporting data featurization, ML model training, ML model deployment, ML model inference and ML model monitoring.
  • Effectively collaborate with members within a fully integrated team to facilitate execution on projects within established timelines
  • Foster a driven, fast-paced, dynamic, and fun environment in which to do rigorous science

Scribe Therapeutics focuses on genetic medicine by utilizing CRISPR technology to develop solutions for genetic diseases. CRISPR acts like molecular scissors that can cut and edit DNA, allowing for the potential correction of genetic defects. The company collaborates with healthcare providers, research institutions, and pharmaceutical companies to create and license gene therapies. Scribe Therapeutics is also working on advanced delivery methods to enable in vivo genetic medicine, which means treating diseases directly within the body. Their technology is designed for high precision, allowing for targeted interventions that can address specific genetic variants. The goal of Scribe Therapeutics is to advance the field of genetic medicine and provide effective treatments for genetic disorders.

Company Size

51-200

Company Stage

Series B

Total Funding

$140M

Headquarters

Alameda, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Scribe's partnership with Prevail includes $75 million upfront and $1.5 billion milestones.
  • The expanded Sanofi partnership, valued at $1.2 billion, boosts Scribe's market influence.
  • Experienced leadership with Dr. Aarif Khakoo and Dr. Maria Mirotsou enhances R&D efforts.

What critics are saying

  • Competition from Beam Therapeutics may impact Scribe's market share.
  • Legal disputes over CRISPR patents could pose challenges for Scribe's technologies.
  • Regulatory scrutiny on gene editing may delay Scribe's product development timelines.

What makes Scribe Therapeutics unique

  • Scribe's XE platform achieves over 75% editing efficiency in non-human primates' liver cells.
  • The company offers novel epigenetic editing capabilities with enhanced specificity and potency.
  • Scribe's proprietary CRISPR by Design platform enables precise allele-specific targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

13%
Business Wire
Mar 7th, 2025
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference

Scribe Therapeutics presents data on its Epigenetic Long-Term X-Repressor technology at the 2025 Keystone Symposia on Precision Genome Engineering conference.

Business Wire
Jan 9th, 2025
Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Scribe Therapeutics to present at the 43rd Annual J.P. Morgan Healthcare Conference.

Business Wire
May 10th, 2024
Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing Of Hepatocytes In Nhps, By An Engineered Xe Genome Editor; Showcases Novel Epigenetic Editing Capabilities At 2024 Asgct Annual Meeting

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on its X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place in Baltimore, MD, and virtually.The data described in the company’s oral presentations and poster session showcase the dramatic potency, safety, and specificity of the novel XE genome editing and ELXR epigenetic editing platforms and the company's developments in successfully advancing these technologies into large animal models, including non-human primates.“ A major challenge in the field has been to achieve saturating levels of genome editing, at therapeutically relevant doses, with molecules that have better safety and delivery characteristics than CRISPR-Cas9—this has not been possible to date,” said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe. “ For the first time, Scribe has demonstrated that the holistic engineering of a wholly unique and highly potent CRISPR enzyme can enable this goal. We have demonstrated that our XE platform can achieve editing rates of greater than 75% in the liver of NHPs, theoretically targeting all hepatocytes, while not displaying any detectable off-target effects in primary human cells.”“ Furthermore, we were thrilled to unveil a taste of the engineering behind Scribe’s ELXR epigenetic editing platform and present data elucidating the effectiveness of our comprehensive engineering approach compared to previous methodologies,” Dr. Oakes said. “ We believe this positions Scribe as the only company to have engineered, from the ground up, novel CRISPR genome editing and epigenetic editing platforms that can meet and often exceed the field’s expectations regarding therapeutically relevant potency and specificity.”Additional highlights on the developments of the XE platform and application in vivo include:Presentation: Engineering CasX to Create a Gene Editor with Potent Activity in Non-Human PrimatesUsing a variety of holistic engineering approaches, Scribe has created X-Editor molecules that are >100 steps in sequence space removed and >100-fold more potent than the naturally occurring CRISPR predecessorsXE achieves at or near-saturating levels of editing across a broad range of tissue types, including the eye, CNS, cardiac and skeletal muscle, and liver using either AAV or LNPXE is highly potent in non-human primate studies, achieving >75% editing in the liver and saturating editing at <1.5mg/kgWhen tested at different sites, XE is highly specific, demonstrating no detectable off-target editing at doses 10-fold higher than the effective dose in primary human hepatocytesScribe continues to expand the XE platform by engineering molecules with customizable genomic targetability by modifying the PAM recognition of the XE platformPresentation: AAV-Mediated Delivery of a Novel CasX-Editor Molecule Achieves Allele-Specific and Potent Editing of P23H Rhodopsin in a Mouse Model of Retinitis PigmentosaXE and AAV cargo engineering enables safe and selective XE delivery and editing in rod photoreceptors when administered subretinallyScribe demonstrates for the first time the use of XE to achieve allele-specific editing of the P23H.RHO locus, in an in vitro system and a phenotypically relevant in vivo model

Business Wire
Apr 22nd, 2024
Scribe Therapeutics To Present On Advances In Crispr Genome And Epigenome Editing At The 2024 American Society Of Gene Cell Therapy (Asgct) Annual Meeting

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place at the Baltimore Convention Center in Baltimore, MD, and virtually from May 7-11, 2024.Scribe will deliver two oral presentations and one poster presentation showcasing the latest developments in its CRISPR X-Editor (XE) and Epigenetic Long-Term X-Repressors (ELXR) technologies enabled by its CRISPR by Design™ approach. The company’s presentations will include data demonstrating the potent editing activity of XE in non-human primates, the potential for XE to address P23H.RHO-related autosomal dominant retinitis pigmentosa (adRP), and the comprehensive engineering approach to creating highly potent ELXRs.More details on each presentation are listed below and the full abstracts are available on the ASGCT meeting website.Oral presentation title: AAV-Mediated Delivery of a Novel CasX-Editor Molecule Achieves Allele-Specific and Potent Editing of P23H Rhodopsin in a Mouse Model of Retinitis PigmentosaAbstract number: 180Session title: Ophthalmic and Auditory: Disease FocusDate: Thursday, May 9, 2024Time: 2:15 - 2:30 p.m. ETLocation: Room 318-323Speaker: Cécile Fortuny, Ph.D., Senior Scientist II at ScribeOral presentation title: Engineering CasX to Create a Gene Editor with Potent Activity in Non-Human PrimatesAbstract number: 155Session title: Gene Disruption and ExcisionDate: Thursday, May 9, 2024Time: 2:55 - 3:12 p.m. ETLocation: Ballroom 3Speaker: Addison Wright, Ph.D., Principal Scientist at ScribePoster title: Comprehensive Engineering of a CasX-Based Repressor to Create Highly Potent Epigenetic EditorsAbstract number: 1670Session title: Epigenetic Editing and RNA EditingDate: Friday, May 10, 2024Time: 12:00 - 7:00 p.m. ETLocation: Exhibit HallSpeaker: Jason Fernandes, Ph.D., Principal Scientist at ScribeAbout Scribe TherapeuticsScribe Therapeutics is revolutionizing the development of optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases

Neuro Central
Dec 20th, 2023
Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology

Scribe Therapeutics appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology.

INACTIVE